A previously healthy young man in Greece who later developed atypical hemolytic uremic syndrome (aHUS) improved rapidly after being treated with the complement inhibitor Soliris (eculizumab), which helped his heart function recover over time, but delayed therapy was linked to permanent kidney failure requiring dialysis. “This case emphasizes…